Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-6148
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines ; volume:10 ; number:1 ; day:30 ; month:9 ; year:2014 ; pages:1-9 ; date:12.2014
BMC veterinary research ; 10, Heft 1 (30.9.2014), 1-9, 12.2014
- Urheber
-
Hsiao, Yen-Ling
- Beteiligte Personen und Organisationen
-
Hsieh, Tai-Zu
Liou, Chian-Jiun
Cheng, Yeong-Hsiang
Lin, Chung-Tien
Chang, Chi-Yao
Lai, Yu-Shen
SpringerLink (Online service)
- DOI
-
10.1186/s12917-014-0229-0
- URN
-
urn:nbn:de:1111-2016080554194
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hsiao, Yen-Ling
- Hsieh, Tai-Zu
- Liou, Chian-Jiun
- Cheng, Yeong-Hsiang
- Lin, Chung-Tien
- Chang, Chi-Yao
- Lai, Yu-Shen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors
Global protein analyses of canine mammary gland tumors
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors
Global protein analyses of canine mammary gland tumors
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors